Molecular Imaging of Melanoma VEGF-expressing Tumors through [<sup>99m</sup>Tc]Tc-HYNIC-Fab(Bevacizumab)
We present the development and evaluation of [<sup>99m</sup>Tc]Tc-HYNIC-Fab(bevacizumab), a novel molecular VEGF expression imaging agent that may be used for precision medicine in melanoma and potentially in other VEGF-expressing tumors.
Authors
- Eduardo Savio (ORCID: https://orcid.org/0000-0002-2358-194X)
- Lucía Alfaya (ORCID: https://orcid.org/0009-0002-2409-7225)
- A. Reyes (ORCID: https://orcid.org/0000-0001-8647-9697)
- Carolina Perroni (ORCID: https://orcid.org/0000-0002-6790-4851)
- Pablo Cabral (ORCID: https://orcid.org/0000-0001-7344-2027)
- María Fernanda García (ORCID: https://orcid.org/0000-0002-2918-5761)
- Ximena Camacho (ORCID: https://orcid.org/0000-0002-0755-3834)
- Andrea Paolino
- Hugo Cerecetto (ORCID: https://orcid.org/0000-0003-1256-3786)
- Mirel Cabrera (ORCID: https://orcid.org/0000-0002-5225-1106)
- Marcos Tassano (ORCID: https://orcid.org/0000-0001-6685-4656)
- Juan Pablo Gambini (ORCID: https://orcid.org/0000-0001-5368-3464)
- Marcelo Fernández
Institutions
- Universidad de la República de Uruguay (UY)
- Hospital de Clínicas (UY)
- Centro Uruguayo de Imagenología Molecular (UY)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2024-08-12
- DOI
- https://doi.org/10.2174/0118715206294297240805073550
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00